Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6002
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuf, I. U.-
dc.contributor.authorBaque, E.-
dc.contributor.authorColditz, P. B.-
dc.contributor.authorChatfield, M. D.-
dc.contributor.authorWare, R. S.-
dc.contributor.authorBoyd, R. N.-
dc.contributor.authorGeorge, J. M.-
dc.date.accessioned2024-06-20T00:29:29Z-
dc.date.available2024-06-20T00:29:29Z-
dc.date.issued2023-
dc.identifier.citationPediatric Research, 2023 (93) 6 p.1721-1727en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6002-
dc.description.abstractBackground: To determine the diagnostic accuracy of Hammersmith Neonatal Neurological Examination (HNNE) at 30–32 weeks postmenstrual age (PMA, ‘Early’) and term equivalent age (TEA) in infants born <31 weeks PMA to predict cognitive outcomes at 12 months corrected age (CA). Methods: Prospective cohort study of 119 infants (73 males; median 28.4 weeks gestational age at birth) who underwent Early and TEA HNNE. At 12 months CA, 104 participants completed Bayley Scales of Infant and Toddler Development, 3rd Edition, (Bayley-III). Optimum cut-off points for each HNNE subscale were determined to establish diagnostic accuracy for predicting adverse cognitive outcomes on the Bayley-III Cognitive Composite Scale (≤85). Results: The best diagnostic accuracy for HNNE total score at 30–32 weeks PMA predicting cognitive impairment occurred at cut-off ≤16.7 (sensitivity (Se) = 71%, specificity (Sp) = 51%). The Abnormal Signs subscale demonstrated the best balance of sensitivity/specificity combination (Se = 71%, Sp = 71%; cut-off ≤1.5). For HNNE at TEA, the total score at cut-off ≤24.5 had Se = 71% and Sp = 47% for predicting cognitive impairment. The Tone Patterns subscale demonstrated the strongest diagnostic accuracy at TEA (Se = 71%, Sp = 63%; cut-off ≤3). Conclusions: Early and TEA HNNE demonstrated moderate diagnostic accuracy for cognitive outcomes at 12-months CA in infants born <31 weeks gestational age. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry; Trial Registration Number: ACTRN12613000280707; web address of trial: http://www.ANZCTR.org.au/ACTRN12613000280707.aspx. Impact: Early Hammersmith Neonatal Neurological Examination (HNNE) assessment at 30–32 weeks postmenstrual age has moderate diagnostic accuracy for cognitive outcomes at 12 months corrected age in infants born <31 weeks gestation.Early HNNE at 30–32 weeks has stronger predictive validity than HNNE at term equivalent age.Early HNNE may provide an early marker for risk-stratification to optimise the planning of post-discharge support and follow-up services for infants born preterm.-
dc.language.isoEnglish-
dc.titleNeurological examination at 32-weeks postmenstrual age predicts 12-month cognitive outcomes in very preterm-born infants-
dc.typeArticle-
dc.identifier.doi10.1038/s41390-022-02310-6-
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2019277515&from=export-
dc.relation.urlhttp://dx.doi.org/10.1038/s41390-022-02310-6-
dc.identifier.journaltitlePediatric Research-
dc.identifier.risid4570-
dc.description.pages1721-1727-
dc.description.volume93-
dc.description.issue6-
item.languageiso639-1English-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

46
checked on Nov 26, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.